Palm oil

Palm Oil (Elaeis guineensis Jacq.): A Comprehensive Reference

1. Identity

Botanical and Scientific Names

The oil palm, scientifically known as Elaeis guineensis Jacq., is a tropical tree species native to West Africa. A second species, Elaeis oleifera (Kunth) Cortés (the American oil palm), is less commercially prevalent but notable in hybridization research. Interspecific hybridization of Elaeis oleifera × E. guineensis (O×G) has been exploited with the main aim of developing disease-resistant varieties. The fruit of E. guineensis yields two distinct oils: palm oil, extracted from the fleshy outer mesocarp, and palm kernel oil, extracted from the seed (kernel) within the hard endocarp.

Physical Characteristics

Palm oil has a balanced fatty acid composition between saturated fatty acids (approximately 50%) and unsaturated fatty acids (MUFA 39% and PUFA 10%, mostly as linoleic acid). The melting point of palm oil ranges from 32°C to 39°C, contributing to its semi-solid consistency at room temperature. In its crude, unrefined state, palm oil is characterised by a deep orange-red colour derived from its very high carotenoid content.

Common Forms and Preparations

Several commercially and nutritionally distinct forms of palm oil exist, determined by the degree of processing applied to the crude oil.

• Crude Palm Oil (CPO): The minimally processed oil obtained directly from the mesocarp by pressing and boiling. CPO represents the richest natural source of carotenoids (500–700 ppm), tocopherols and tocotrienols (600–1,200 ppm), all contributing to its stability and nutritional properties.
• Red Palm Oil (RPO): Obtained from the fruit of Elaeis guineensis, minimally processed RPO retains high levels of carotenoids, including alpha-carotene, beta-carotene, and lycopene, as well as tocopherols, tocotrienols, polyphenols, and minor components such as phytosterols and squalene.
• Refined, Bleached, and Deodorised (RBD) Palm Oil: The refining process of palm oil involves steps like degumming, bleaching, and deodorisation to remove impurities and improve stability and flavour. Refined palm oil loses some of its antioxidant properties, including carotenoids and vitamin E.
• Fractionated Forms — Palm Olein and Palm Stearin: Fractionation is the most common method of extracting useful products from refined palm oil. It entails physically separating the oil into liquid and solid fractions using crystallisation. The liquid fat fractions or "oleins" contain unsaturated molecules, making them suitable for cooking oils, while the solid fat fractions or "stearins" contain more saturated molecules and are used in products like margarine and vegetable ghee. Oleins and stearins can then be fractionated further to create super oleins, super stearins, and harder palm mid-fractions.
• Palm Kernel Oil (PKO): Derived from the kernel rather than the mesocarp. Palm kernel olein is lighter than palm olein and richer in medium-chain fatty acids like lauric and myristic acids, properties that impart excellent oxidative stability.
• Tocotrienol/Tocopherol Concentrates: A commercial process is in operation to obtain a 99% pure concentrate of the tocopherols and tocotrienols from the palm fatty acid distillate, the byproduct of physical refining. This concentrate is used in health supplements.

2. Traditional and Historical Use

West and Central Africa: Ancient Origins

Archaeological evidence shows that palm fruit and kernels and their oil already formed an integral part of West African diets 5,000 years ago. For thousands of years, the oil palm — indigenous to West Africa — has had an intimate relationship with humans. An explosive expansion of oil palm groves throughout western and central Africa in the wake of a dry period around 2,500 years ago enabled human migration and agricultural development; in turn, humans facilitated oil palm propagation through seed dispersal and slash-and-burn agriculture.

There is evidence for early use in Ghana during the late Holocene. The oil palm is also prominent in culinary and material cultures elsewhere in the region, from Senegal to Angola, where it has been consumed and traded for centuries. Throughout West and Central Africa and as far east as Tanzania, its oils are used in cooking, soap, and as a light fuel. It is favoured as a condiment for fufu, and it can be used to make palm wine and as a medicine.

The fruit was processed into palm oil by women through a time-consuming and labour-intensive process involving repetitively boiling and filtering the fresh fruits with water — similar methods are still largely used throughout West Africa. While pure red palm oil was derived from the palm fruit's fleshy outer mesocarp, women also cracked the palm kernels to make palm kernel oil.

In the traditional songs of many countries of West and Central Africa, the oil palm is called the "tree of life." For centuries, indigenous groups have utilised different parts of the oil palm tree, from the fruit and leaves to fibres and trunks, while also employing traditional methods of cultivation and processing.

Traditional Medicinal Use

In traditional West African medicine, palm oil has been used for various purposes, including wound healing, skin conditions, and as a source of energy. It is believed to possess anti-inflammatory properties and is sometimes applied topically to treat burns and skin irritations. It was offered during traditional rites, used in local medicine, and exchanged in trade long before modern currency.

European Industrial Adoption and Global Spread

There are several written records of the culinary use of palm oil from the documents of European travellers to West Africa that date from the middle of the fifteenth century onwards. Palm oil became a key material in the Industrial Revolution in Europe. Manufacturers found it to be an ideal substitute for the animal-based fatty wax traditionally used in soap manufacturing and candle making, and it was also perfectly suited as an industrial lubricant for oiling engine parts and in tinplate production. From the 1900s onwards, European-run plantations were established in Central Africa and Southeast Asia, and world trade in palm oil continued to grow, reaching 250,000 tonnes per annum by 1930.

Among major oilseed crops, the palm tree fruit accounts for the smallest percentage (5.5%) of all cultivated land for oils and fats globally, but produces the largest percentage (32%) of total output.

3. Key Constituents and Active Compounds

Fatty Acid Profile

The chemical composition of palm oil is primarily triglycerides, with palmitic acid (C16:0) being the most abundant fatty acid, typically accounting for around 44% of the total fatty acid content. Palm oil contains approximately 40% oleic acid (monounsaturated fatty acid), 10% linoleic acid (polyunsaturated fatty acid), 45% palmitic acid, and 5% stearic acid (saturated fatty acid). This roughly equal balance between saturated and unsaturated fatty acids distinguishes palm oil from most other tropical fats such as coconut oil.

Carotenoids

Red palm oil retains high levels of carotenoids, including alpha-carotene, beta-carotene, and lycopene. Having some quantity of beta-carotene increases the internal (nutritional) value and provides colour as well as antioxidant properties to palm oil. These carotenoids function as provitamin A precursors, meaning they can be converted in the body to retinol (vitamin A). The refining process substantially degrades carotenoid content, which is why RPO is nutritionally distinct from RBD palm oil.

Tocopherols and Tocotrienols (Vitamin E Family)

Palm oil is rich in tocotrienols (T3s), a type of vitamin E that has garnered considerable research interest as it exhibits anti-inflammatory as well as antioxidant characteristics that are comparable to or exceed those of tocopherols. There are four analogues (α-, β-, γ-, δ-) of each form of vitamin E, meaning there are eight isoforms in total: α-, β-, δ-, γ-tocotrienol and α-, β-, δ-, γ-tocopherol.

Vitamin E is a non-specific chain-breaking antioxidant that can help to inhibit polyunsaturated fatty acid oxidation and can thus act as a radical scavenger. Tocotrienols have been reported to be natural inhibitors of cholesterol synthesis. At nanomolar concentration, α-tocotrienol, but not α-tocopherol, prevents neurodegeneration; on a concentration basis, this finding represents the most potent of all biological functions exhibited by any natural vitamin E molecule.

Phytosterols

Phytosterols are a subclass of sterols — plant-derived compounds with structures similar to cholesterol — and are natural constituents of the mesocarp and kernel fractions in palm oil. Identified phytosterol molecules in palm oil include campesterol, stigmasterol, beta-sitosterol, Delta5-avenasterol, Delta5,24-stigmastadienol, fucosterol, and clerosterol.

Oil Palm Phenolics (OPP)

A potential agent, oil palm phenolics (OPP), recovered from the aqueous waste of the oil palm milling process, contains numerous water-soluble phenolic compounds. It has been postulated that OPP has cardioprotective effects via several mechanisms including the cholesterol biosynthesis pathway, antioxidant, and anti-inflammatory properties.

Mechanisms of Action — Summary

• Antioxidant activity: The antioxidant properties of carotenoids, tocopherols, and tocotrienols, exerted mainly against reactive oxygen species (ROS), play a role in aging, cardiovascular disease prevention, and cancer prevention.
• Anti-inflammatory activity: Data from experimental models and human studies show that tocotrienol administration can inhibit the release of various inflammatory mediators that contribute to age-related disease by enhancing oxidative stress responses, reducing melanin production and skin damage, and preventing cardiovascular disease and stroke.
• Neuroprotection: Evidence exists to show that tocotrienols possess neuroprotective, anticancer, and anti-osteoporosis properties.
• Provitamin A conversion: Alpha- and beta-carotene in RPO serve as precursors to retinol, addressing vitamin A deficiency through dietary ingestion.
• Platelet aggregation modulation: In hypercholesterolaemic subjects, supplementation with tocotrienols significantly reduced plasma thromboxane B2 and platelet aggregation in response to ADP stimulation.

4. Scientific Evidence by Area of Use

4.1 Vitamin A Deficiency (VAD)

This is the area with the most consistent and robust clinical evidence for red palm oil as a nutritional intervention. Deficiency of vitamin A or retinol is a public health problem, listed as the most widespread nutritional deficiency worldwide. According to the WHO, about 190 million preschool children in underdeveloped countries, especially in Africa and Southeast Asia, are vitamin A deficient. Vitamin A deficiency in children causes visual impairment, blindness, stunting, anaemia, respiratory disease, increased risk of infection, and mortality due to common childhood infections such as diarrhoea.

Clinical Evidence — Meta-analysis (2017): After conducting a comprehensive literature search, nine randomised controlled trials (RCTs) were included in a meta-analysis. Overall, the results indicated that RPO reduced the risk of VAD (relative risk = 0.55; 95% CI: 0.37, 0.82; p = 0.003), increased serum retinol levels in both children (p < 0.00001) and adults (p = 0.002), and increased beta-carotene levels (p = 0.01). However, RPO supplementation did not have a significant overall effect on serum alpha-carotene levels (p = 0.06), body weight (p = 0.45), or haemoglobin levels (p = 0.72). The results also showed that a low level of RPO intake (≤8 g RPO) could increase serum retinol concentrations, whereas RPO intake above 8 g did not lead to further increase. This meta-analysis demonstrated that RPO might be effective for preventing or alleviating VAD.

Clinical Evidence — Early Controlled Trial (Indonesia): Red palm oil (4 mL daily) was given to children aged 1 to 5 years in two communities as a source of provitamin A. Children were examined clinically and biochemically before and during treatment. Similar examinations were conducted in two control villages, one receiving decolourised palm oil and the other no supplement. Xerophthalmia decreased significantly from a 7% incidence in one treated village; in the other it remained at about 3%. Serum vitamin A levels increased significantly in both treated villages. There was no significant change in incidence of xerophthalmia or blood vitamin A levels in control villages.

Clinical Evidence — School Children (Burkina Faso): A clinical trial published in Nutrition Journal (2006) found that incorporating red palm oil into school meals positively impacted vitamin A status in school-age children in Burkina Faso, a region where vitamin A deficiency is widespread.

Clinical Evidence — Controlled Trial (Malaysia, 2024): A double-blinded randomised controlled trial demonstrated that supplementation with red palm olein-enriched biscuits improved levels of provitamin A carotenes, iron, and erythropoiesis in vitamin A-deficient primary schoolchildren (European Journal of Nutrition, 2024).

Carotenoid bioavailability evidence: A multicenter 20-week trial in 400 healthy volunteers across five European regions compared serum responses to 15 mg of carotenoids from red palm oil versus other carotenoid sources (lutein-rich marigold extract or lycopene-rich tomato extract) in corn oil, or corn oil placebo. The red palm oil-supplemented group showed marked increases in alpha-carotene (14-fold) and beta-carotene (5-fold).

Evidence strength: Strong for red palm oil as a food-based strategy to increase serum retinol and beta-carotene in deficient populations, supported by multiple RCTs and a meta-analysis. The effect on haemoglobin (anaemia) was not significant in pooled analysis.

4.2 Cardiovascular Health and Lipid Profiles

This is a contested area with mixed and heterogeneous clinical evidence. The cardiovascular effects of palm oil depend significantly on what dietary fat it replaces or is compared to.

Meta-analysis comparing palm oil to unsaturated fats: A meta-analysis published in Circulation found that palm oil significantly increased total cholesterol by 0.32 mmol/L (95% CI: 0.19, 0.44), increased LDL cholesterol by 0.20 mmol/L (95% CI: 0.09, 0.32), and increased HDL cholesterol by 0.02 mmol/L (95% CI: 0.01, 0.04) as compared with control oils (predominantly unsaturated vegetable oils). Considerable heterogeneity in study results was partly explained by the type of control oil used, funding source, geographical location, and level of intake of the test oil.

Meta-analysis comparing palm oil to trans fats: Comparison of palm oil-rich diets with diets rich in trans fatty acids showed significantly higher concentrations of HDL cholesterol and apolipoprotein A-I, and significantly lower apolipoprotein B, triacylglycerols, and TC/HDL cholesterol ratio. Both favourable and unfavourable changes in coronary heart disease/cardiovascular disease risk markers occurred when palm oil was substituted for the primary dietary fats, whereas only favourable changes occurred when palm oil was substituted for trans fatty acids.

Meta-analysis vs. unsaturated fatty acids: A separate systematic review concluded that palm oil does not induce increases in cardiovascular disease risk-related biomarkers relative to unsaturated fatty acids. Palm oil consumption had no significant effects on blood total cholesterol (WMD: −0.01 mmol/L; p = 0.82) and LDL-c (WMD: −0.05 mmol/L; p = 0.10) and triglyceride concentrations (WMD: 0.00 mmol/L; p = 0.96), relative to the effects of unsaturated fatty acid consumption. Subgroup analyses revealed that palm oil has a beneficial effect on HDL cholesterol levels when more than 30% of total dietary energy was constituted by fat.

Systematic review on CVD events: A systematic review retrieved 2,738 citations for stroke (with one included study) and 1,777 citations for coronary heart disease (CHD) with four included studies. Palmitic acid was reported to be associated with risk of myocardial infarction (OR 2.76; 95% CI = 1.39–5.47), whereas total SFA intake was not significant for risk of MI. The review could not establish strong evidence for or against palm oil consumption relating to cardiovascular disease risk and cardiovascular disease-specific mortality.

Oil palm phenolics on cholesterol biosynthesis: Few studies have investigated the effects of palm oil per se, and the main reason it has been associated with negative health effects is the relatively high content of saturated fatty acids, particularly palmitic acid. However, more recent investigations seem to have reconsidered the negative role of dietary SFAs as a risk factor for cardiovascular diseases, showing that not only the type of fat, but also the triglyceride structure, plays a role in cholesterolaemia.

Plant sterol-enriched palm oil RCT: In a placebo-controlled double-blinded trial, significant improvement in lipid profile was reported, as evidenced by a significant reduction in total cholesterol and LDL cholesterol, in hyperlipidaemic individuals who consumed plant sterol-enriched palm oil as a replacement for usual palm oil for cooking.

Evidence strength: Mixed and context-dependent. Palm oil raises LDL cholesterol compared to oils high in unsaturated fats, but performs favourably relative to trans fats. Evidence on hard CVD endpoints (MI, stroke) is insufficient to draw firm conclusions. The high degree of heterogeneity across studies limits definitive guidance.

4.3 Tocotrienols: Neuroprotection and Cerebrovascular Health

Clinical Trial — White Matter Lesions (2014, Stroke): Previous cell-based and animal studies showed mixed tocotrienols are neuroprotective, but the effect was yet to be proven in humans. A study evaluated the protective activity of mixed tocotrienols in humans with white matter lesions (WMLs), which are regarded as manifestations of cerebral small vessel disease, reflecting varying degrees of neurodegeneration and tissue damage with potential as a surrogate endpoint in clinical trials. A total of 121 volunteers aged ≥35 years with cardiovascular risk factors and MRI-confirmed WMLs were randomised to receive 200 mg mixed tocotrienols or placebo twice a day for 2 years.

Evidence strength: Preliminary. Animal models have shown compelling neuroprotective effects of tocotrienols, including reduced infarct volume after stroke. One RCT in humans using WML volume as a surrogate endpoint has been conducted. This area requires larger, longer-duration trials with clinical endpoints before firm conclusions can be drawn.

4.4 Tocotrienols: Platelet Aggregation and Thrombosis Risk

Clinical Evidence: The inhibitory effect of tocotrienols on platelet aggregation was first reported by Qureshi et al., who showed that supplementation of a tocotrienol-enriched diet reduced plasma thromboxane B2 in a swine model. This finding was further corroborated by several animal models fed with tocotrienol-enriched diets. In hypercholesterolaemic subjects, supplementation of tocotrienols significantly reduced plasma thromboxane B2 and platelet aggregation in response to ADP stimulation.

Evidence strength: Preclinical evidence is consistent. Human clinical evidence is limited to small and short-term studies. No large-scale RCTs have confirmed clinical thrombotic outcomes.

4.5 Vascular Function

RCT — Palm Tocotrienols and Carotenes (2016, PubMed PMID 27760402): Ninety men and women (aged 18–70 years, BMI 20–45 kg/m²) with type 2 diabetes, impaired fasting glucose, and/or elevated waist circumference were randomised to consume either TRF-80 (420 mg/day tocotrienol + 132 mg/day tocopherol), CC-60 (21 mg/day carotenes), or placebo (palm olein) supplements for 8 weeks. Plasma alpha- and beta-carotene and alpha-, delta-, and gamma-tocotrienol concentrations increased in CC-60 and TRF-80 groups, respectively, compared to placebo. However, CC-60 and TRF-80 supplementation had no effects — superior or detrimental — on vascular function or CVD risk factors.

Evidence strength: This well-designed short-term RCT found that supplementation successfully raised circulating levels of palm bioactives but produced no measurable change in vascular function over 8 weeks. The duration may have been insufficient to detect changes in hard endpoints.

4.6 Cancer — Palmitic Acid and Emerging Concerns

Specific studies on dietary palmitic acid or palm oil and the risk of cancer development are scanty, and the evidence is not convincing. Possible membrane protein modifications by palmitoylation and myristoylation may lead to alterations in localisation and function of key proteins for tumour suppression. In vitro and in vivo studies have suggested that specific fatty acids could promote cell invasiveness or metastasis. However, only confusing results have been obtained on the action of selected fatty acids in cell signalling transduction pathways, particularly in cell proliferation and apoptosis.

Recent studies have shown that a palm oil-rich diet fed to mice for 4 weeks led to changes in liver protein levels and S-palmitoylation with increased tumour risk factors. Palmitic acid or high-fat diets specifically promote metastasis of oral cancer and melanoma in a CD36-dependent manner. Long-term adaptation to PA increases colorectal cancer cell proliferation in a beta-adrenergic receptor-dependent manner and promotes breast cancer formation. These findings are from animal and cell-culture studies and have not been replicated in human dietary intervention trials.

There is considerable evidence that, in addition to known risk factors, dietary fat intake plays an important role in determining cancer risk. Tocotrienol administration — a bioactive component of palm oil — has been shown to prevent cardiovascular disease and stroke-related neurodegeneration in preclinical and some human study contexts. Evidence also shows that tocotrienols possess anticancer properties, though these remain at the preclinical stage.

Evidence strength: The cancer-related evidence with respect to palmitic acid is predominantly from in vitro and animal models. Human epidemiological and dietary intervention data are insufficient to establish a causal link between palm oil consumption at normal dietary levels and cancer risk. The anticancer potential of tocotrienols is promising in preclinical models but unconfirmed in humans.

4.7 Tocotrienols in Type 2 Diabetes

In a pilot study where patients with type 2 diabetes mellitus were recruited and given 6 mg/kg/day of tocotrienol-rich fraction (TRF), reductions in total cholesterol, LDL, and triglycerides, in addition to plasma glucose and glycated haemoglobin (HbA1c) levels, were detected after 60 days. This was a pilot study with significant limitations in sample size and study design, and findings should be regarded as preliminary.

Evidence strength: Preliminary. Pilot data only; no large-scale RCTs specifically investigating palm tocotrienols as an adjunct in type 2 diabetes management have been published.

5. Body Systems and Health Areas of Association

• Immune and visual system: Via provitamin A carotenoids — prevention of xerophthalmia, night blindness, and immune deficiency associated with VAD. This is the best-supported area of clinical evidence.
• Cardiovascular system: Oil palm phenolics have shown cardioprotective effects via several mechanisms including the cholesterol biosynthesis pathway, antioxidant, and anti-inflammatory properties. The impact on lipid profiles is real but direction-dependent on the dietary context.
• Nervous system: Data from experimental models and human studies show that tocotrienol administration can inhibit the release of various inflammatory mediators and prevent cardiovascular disease and stroke-related neurodegeneration. The clinical evidence in humans remains limited to one notable RCT.
• Haematological system: Tocotrienols have shown modulation of platelet aggregation and thromboxane B2 in hypercholesterolaemic subjects. Platelet aggregation, a pathophysiological process by which platelets adhere at disrupted vascular sites, is critical for haemostatic plug formation. High platelet aggregation activity promotes formation of thrombus and disturbance of blood flow, leading to cardiovascular diseases.
• Skin and integument: Preclinical and small-scale clinical studies suggest that RPO bioactives can mitigate oxidative stress, modulate inflammatory pathways, and improve skin barrier function.
• Skeletal system: Documented evidence indicates that tocotrienols exhibit antioxidant, neuroprotection, anticancer, and antidiabetic attributes; anti-osteoporosis properties have also been described.

6. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn directly from published human studies. They are not recommendations.

• Red palm oil for vitamin A deficiency in young children: 4 mL of red palm oil daily, given to children aged 1 to 5 years as a source of provitamin A in an Indonesian clinical trial.
• RPO for vitamin A status — threshold dose: Low-level RPO intake (≤8 g RPO) was found to increase serum retinol concentrations, whereas RPO intake above 8 g did not lead to further increase of serum retinol concentrations.
• Palm-based carotene supplement: CC-60 provided 21 mg/day carotenes (from palm) for 8 weeks in a randomised controlled trial in adults with type 2 diabetes, impaired fasting glucose, and/or elevated waist circumference.
• Palm tocotrienol-rich fraction (TRF): TRF-80 supplementation in the same 8-week RCT consisted of 420 mg/day tocotrienol + 132 mg/day tocopherol.
• Mixed tocotrienols for white matter lesions: 200 mg mixed tocotrienols or placebo, taken twice daily for 2 years, in 121 volunteers aged ≥35 years with cardiovascular risk factors and MRI-confirmed white matter lesions.
• TRF for type 2 diabetes (pilot): 6 mg/kg/day of tocotrienol-rich fraction (TRF) for 60 days in patients with type 2 diabetes mellitus.
• Palmvitee concentrate (healthy adults): Approximately 18 mg, 42 mg, and 240 mg of palm oil vitamin E concentrate (Palmvitee) were used in a single-arm study in healthy subjects, with significant reduction in total cholesterol observed after 30 days, though no changes were detected for LDL and HDL.

7. Safety Considerations

Processing Contaminants: MCPD Esters and Glycidyl Fatty Acid Esters

The European Food Safety Authority (EFSA) assessed the risks for public health of glycidyl fatty acid esters (GE), 3-monochloropropanediol (3-MCPD), and 2-monochloropropanediol (2-MCPD) and their fatty acid esters. These substances form during food processing, in particular when refining vegetable oils at high temperatures (approximately 200°C). The highest levels of GE, as well as 3-MCPD and 2-MCPD (including esters), were found in palm oils and palm fats, followed by other oils and fats.

EFSA concluded that glycidyl fatty acid esters are a concern for public health because they are genotoxic and carcinogenic — they can damage DNA and cause cancer. Glycidol itself is categorised as probably carcinogenic to humans. Latest scientific studies indicate an almost entire release of glycidol from fatty acid esters within the human digestive tract.

EFSA set a tolerable daily intake (TDI) of 0.8 micrograms per kilogram of body weight per day (µg/kg bw/day) for 3-MCPD and its fatty acid esters, based on evidence linking this substance to organ damage in animal tests. Estimated average and high exposures to 3-MCPD for young age groups, including adolescents (up to 18 years of age), exceed this TDI.

3-MCPD is classified as a potential carcinogen which can deplete kidney function and male fertility in animal studies, while glycidol shows mutagenic properties. Refined palm oil is reported to contain the highest amount of MCPD esters and GE among other refined vegetable oils such as sunflower and soybean oils. These contaminants are a function of the high-temperature refining process, not of crude or minimally processed palm oil per se.

Cardiovascular Risk and Palmitic Acid

Palmitic acid, a saturated fatty acid, is the principal constituent of refined palm oil. In the last few decades, controversial studies have reported potential unhealthy effects of palm oil due to the high palmitic acid content. Palmitic acid was reported to be associated with risk of myocardial infarction (OR 2.76; 95% CI = 1.39–5.47) in one included observational study. However, the triglyceride position of palmitic acid (sn-2 vs. sn-1/sn-3) may modify its physiological impact, and more recent investigations seem to have reconsidered the negative role of dietary SFAs as a risk factor for cardiovascular diseases, showing that not only the type of fat but also the triglyceride structure plays a role in cholesterolaemia.

Differential Risk by Form of Palm Oil

Despite the good quality of crude palm oil, food manufacturing industries require palm oil with a bland and light colour, making refinery a mandatory step. The refining process simultaneously destroys beneficial bioactives (carotenoids, tocotrienols) and generates potentially harmful processing contaminants (MCPD esters, glycidyl esters). Therefore, the safety and nutritional profiles of crude/red palm oil and fully refined RBD palm oil differ substantially.

Lack of Established Drug Interactions

No formal pharmacokinetic drug interaction data for palm oil or its isolated bioactives (tocotrienols, carotenoids) are established in the authoritative literature reviewed. Documented evidence that tocotrienols exhibit antioxidant, neuroprotective, anticancer, and antidiabetic attributes raises theoretical potential for interaction with anticoagulants and lipid-lowering agents, but no clinical interaction studies have been identified in the sources reviewed. The platelet-inhibitory activity of tocotrienols in human studies warrants caution in this context.

Population-Specific Considerations

Vitamin A deficiency is associated with illness and death, especially in preschool-aged children and pregnant women in low- and middle-income countries in Africa and Southeast Asia. For these populations, red palm oil represents a cost-effective, food-based provitamin A source with demonstrated clinical benefit. In well-nourished populations in high-income countries, the primary concern regarding palm oil is its contribution of saturated fat and, for refined forms, processing contaminants.

References

• Madoromae H, Lertcanawanichakul M. Red Palm Oil: Nutritional Composition, Bioactive Properties, and Potential Applications in Health and Cosmetics: A Narrative Review. Molecules. 2025;30(22):4402. PMC12655212.
• Mancini A, et al. Biological and Nutritional Properties of Palm Oil and Palmitic Acid: Effects on Health. Molecules. 2015;20(9):17339–17361. PMC6331788.
• Falade OS, et al. Health-promoting effects of red palm oil: evidence from animal and human studies. Nutrition Reviews. 2017;75(2):98–113.
• Dong S, Xia H, Wang F, Sun G. The Effect of Red Palm Oil on Vitamin A Deficiency: A Meta-Analysis of Randomized Controlled Trials. Nutrients. 2017;9(12):1281. PMC5748732.
• Bloch AS, et al. Short term effects of palm-tocotrienol and palm-carotenes on vascular function and cardiovascular disease risk: A randomised controlled trial. Nutr Metab Cardiovasc Dis. 2016. PMID 27760402.
• Chin KY, et al. Biological Properties of Tocotrienols: Evidence in Human Studies. Int J Mol Sci. 2016;17(11):1682. PMC5133770.
• Teng KT, et al. Effect of palm-based tocotrienols and tocopherol mixture supplementation on platelet aggregation in subjects with metabolic syndrome. PMC5599564.
• Gopalan Y, et al. Clinical Investigation of the Protective Effects of Palm Vitamin E Tocotrienols on Brain White Matter. Stroke. 2014;45(5):1422–1428.
• Fattore E, et al. Effect of palm oil consumption on plasma lipid concentrations related to cardiovascular disease: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2019. PMID 31464396.
• Fattore E, et al. Palm oil and blood lipid-related markers of cardiovascular disease: a systematic review and meta-analysis of dietary intervention trials. Am J Clin Nutr. 2014;99(6):1331–1350. PMID 24717342.
• Ismail SR, et al. Systematic review of palm oil consumption and the risk of cardiovascular disease. PMC5831100.
• Plant Sterol-Enriched Palm Oil Intervention to Improve Lipid Profile and Inflammation Status in Hyperlipidemic Individuals. PMC11478633.
• Ibrahim NI, Fairus S, Mohamed IN. The Effects and Potential Mechanism of Oil Palm Phenolics in Cardiovascular Health: A Review. Nutrients. 2020;12(7):2055. PMC7400923.
• Ibrahim NI, et al. Therapeutic potential of palm oil vitamin E-derived tocotrienols in inflammation and chronic diseases. Food Res Int. 2022.
• Palmitic acid and palmitoylation in cancer: Understanding, insights, and challenges. PMC12347385.
• EFSA CONTAM Panel. Risks for human health related to the presence of 3- and 2-MCPD and glycidyl fatty acid esters in food. EFSA Journal. 2016;14(5):4426.
• EFSA. Revised safe intake for 3-MCPD in vegetable oils and food. 2018.
• Dialogue Earth. Red gold: a history of palm oil in West Africa. 2022.
• Dialogue Earth. Breaking down palm oil. 2022.
• Chemical Composition, Bioactive Constituents, and Functional Value of Chinese Palm Fruit. Foods. 2026;15(10):1618.
• Chemical Characteristics and Nutritional Properties of Hybrid Palm Oils. IntechOpen. 2018.
• ClinicalTrials.gov: Effects of Biscuits Containing Red Palm Oil on School Children with Vitamin A Deficiency. NCT03256123.
• Zeba AN, et al. The positive impact of red palm oil in school meals on vitamin A status: study in Burkina Faso. Nutr J. 2006;5:17. PMC1562437.